Skip to main content
Premium Trial:

Request an Annual Quote

Xention Extends Pact with Ono

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK biopharmaceutical firm Xention said today it has extended its drug discovery agreement with Japanese firm Ono Pharmaceutical for an additional year.

The companies originally signed their two-year agreement in March 2009 and have been successful in identifying multiple compounds, which selectively modulate the function of target ion channels, Xention said.

Xention is applying its ion channel drug discovery platform to identify, design, and synthesize small molecules against ion channels chosen by Ono. Under the agreement, Ono is responsible for pre-clinical, clinical development, and worldwide commercialization of potential new pharmaceutical products resulting from the work.

Funding for the project is being provided by Ono in its entirety. Xention will receive milestone payments if specific drug discovery targets are met and upon Ono achieving certain development and regulatory goals. Xention will also receive royalties based on product sales.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.